Theralase Technologies Inc.

Founded in Toronto, Canada, in 1994, Theralase Technologies Inc. is a clinical-stage pharmaceutical firm. The company's primary focus is the research and advancement of photodynamic compounds (PDCs) and their associated drug formulations, aimed at combating cancer, bacterial infections, and viral diseases within Canada, the United States, and internationally. In addition to its pharmaceutical pipeline, Theralase develops, manufactures, and markets patented and proprietary super-pulsed laser technology. This technology is employed for alleviating chronic knee pain and is also utilized off-label for various nerve, muscle, and joint ailments. A key pharmaceutical candidate, TLD-1433, is currently in Phase II clinical trials for non-muscle invasive bladder cancer that has shown no response to Bacillus Calmette Guérin treatment. The company's laser product line includes the TLC-2000, a superpulsed, visible red laser system designed to expedite healing and diminish pain and inflammation, all while adhering to Maximal Permissible Exposure limits for tissue safety. Relevant accessories are also offered. Furthermore, Theralase provides several controller-less cool laser therapy systems, such as the TLC-900, TLC-300, and TLC-100. Theralase maintains significant research agreements, including collaborations with the University of Manitoba's Medical Microbiology department for the development of coronavirus vaccines and therapies, and with the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company primarily markets its products to healthcare practitioners.